Cardiovascular and Interventional Radiological Society of Europe
Slider
PublicationsCIRSE InsiderCALCIO Enrolment has started!

CALCIO Enrolment has started!

July 31, 2024

CALCIO is a prospective, observational cohort study that is collecting real-world data on the use of intravascular lithotripsy (IVL) with the Shockwave Medical IVL system (Shockwave Medical, Inc.) to disrupt vascular calcifications in patients with chronic limb-threatening ischemia (CLTI). The study was initiated and is co-chaired by Dr. Raman Uberoi, Prof. Peter Reimer and Prof. Christoph Binkert. CALCIO started patient enrolment on July 15, 2024, with the goal of recruiting 400 CLTI patients over the next two years.

Once patient enrolment is complete, an additional two years will be dedicated to the collection of patient follow-up data to ensure the study meets its objectives. Currently, there are several sites enrolled from Germany and the United Kingdom (UK). More centres from Germany, the UK, France, Austria, Italy, Greece and Canada are in the recruitment process and are expected to join soon.

From left to right: CALCIO initiators C. Binkert, R. Uberoi, and P. Reimer.
Dr. Uberoi explains the CALCIO study.

Next Research, CIRSE’s contract research organization (CRO), is the master administrator of CALCIO and is managing the study on a day-to-day basis. Their team asked the CALCIO initiators and principal investigators to share their thoughts on the study’s significance, their experiences so far, and the importance of generating more clinical evidence. They also encouraged other centres to participate in this vital research effort.

Prof. Christoph Binkert (MRI Bahnhof Oerlikon, Zurich, Switzerland) shared: ‘’I think CALCIO is an important registry because it collects real-world data on a very severe problem, as patients with CLTI need to get revascularization and if they have very calcified arteries, this is a big challenge and the current evidence is not sufficient.’’

Prof. Peter Reimer (Klinikum Karlsruhe, Karlsruhe, Germany) said: ‘’As interventional radiologists, we should learn to collect outcome data that looks at the long-term prognosis of patients. This is exactly what we will do with the CALCIO study. We’ll look at the amputation rate and wound healing through the use of IVL. That is why we should all try to enrol as many patients as possible in the CALCIO study.

Dr. Joo-Young Chun, principal investigator (St. George’s University Hospital, England, UK), highlighted what makes CALCIO so special: ‘’ I am very excited to be part of the study! What makes CALCIO quite unique is that it takes real-world patients with very wide inclusion criteria and very few exclusion criteria. I am also happy that the outcome measures are clinically focused. We are talking about CLTI patients, so these are patients with the risk of losing their legs, and we are looking at wound healing and also amputation-free survival. We are not necessarily focusing on how the lesion performs with IVL, but on how the patient does. Another exceptional thing about CALCIO is that we are looking at quality of life, which is quite unusual in such studies, and it would be very interesting to see how patients perceive their treatment and how it is affecting their quality of life.’’

Dr. Raghuram Lakshminarayan, principal investigator (Hull University Teaching Hospital, England, UK), emphasized the significance of addressing calcification: ‘’Calcification is a huge problem for the medical community, especially with peripheral arterial disease. We saw this in the pulmonary system, and we now realize that this is a major issue in peripheral arterial disease, and IVL has come as a new technique in order to try to deal with this problem of calcification in peripheral arteries. CIRSE has set up this unique registry to look at exactly how IVL is going to work over a period of time. There have been a lot of studies, but we want to have a large population to look at over a long period of time for us to get to the bottom of how IVL modifies calcium and the outcomes when we treat these patients. CALCIO is a great registry, and I think you should add every patient with CLTI to this study!’’